Metabolomic Diagnostics Secures $1million in Second Round Funding
News Feb 13, 2015
Metabolomic Diagnostics has secured an additional €750,000 in venture funding bringing the total investment in the company in the past year to €1.5m.
The SOSventures Ireland Fund, as well as the AIB Seed Capital Fund and Enterprise Ireland, have invested in the company, which has developed novel, predictive diagnostic tests for the early detection of pre-eclampsia during pregnancy.
Based in the Hoffmann Business Park, Little Island, Co Cork, Metabolomic Diagnostics currently employs seven people.
“The second round of funding shows the sustained confidence in our pre-eclampsia tests, which are being developed at our site in Little Island in Cork,” said Charles Garvey, CEO Metabolomic Diagnostics.
“With almost 80,000 deaths each year globally as a result of pre-eclampsia, this technology has the potential to save lives and revolutionize pre-natal care.”
Pre-eclampsia is characterized by rapidly increasing blood pressure and elevated protein in urine and once it escalates, the only treatment option is the delivery of the baby, often prematurely.
The result of significant research into metabolomic biomarkers, the diagnostic blood test will be able to detect the risk of pre-eclampsia early on in the pregnancy and ultimately save the lives of women and their babies through personalized medical interventions.
Source of a Potent Greenhouse Gas IdentifiedNews
A study of a Lake Erie wetland suggests that scientists have vastly underestimated the number of places methane-producing microbes can survive—and, as a result, today’s global climate models may be misjudging the amount of methane being released into the atmosphere.READ MORE
Engineering the Gut Microbiome with 'Good' Bacteria May Help Treat Crohn's DiseaseNews
Researchers have singled out a bacterial enzyme behind an imbalance in the gut microbiome linked to Crohn's disease. Replacement of the offending bacteria with "good" bacteria may offer an effective treatment approach.READ MORE
Obese and Anorexic Women Have Low Levels of ‘Feel Good’ NeurosteroidNews
Researchers have found that women at opposite extremes of the weight spectrum have low levels of the neuroactive steroid allopregnanolone, a metabolite of the hormone progesterone. Gas chromatography and mass spectrometry were used to pick up extremely small levels of these chemicals in blood serum, saliva and brain tissue.READ MORE